{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:06:30Z","timestamp":1776744390358,"version":"3.51.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":352,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Pharma B.V.","award":["8224-41473"],"award-info":[{"award-number":["8224-41473"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Erythrodermic mycosis fungoides and S\u00e9zary syndrome are chronic, relapsing-remitting diseases that greatly impacts patients' quality of life (QoL). Mogamulizumab-kpkc (Mogamulizumab) is a novel therapeutic agent for cutaneous T-cell lymphomas with a notable impact on progression-free survival. Qualitative assessment methods allow a broader exploration and greater insight in individual patient experience than quantitative studies. However, there is limited data on the impact of mogamulizumab on health-related QoL. To investigate the impact of erythrodermic cutaneous T-cell lymphoma (E-CTCL) on QoL and the effect of mogamulizumab on the QoL. Semi-structured interview were conducted with seven patients with E-CTCL that were receiving mogamulizumab treatment. Five major themes arose: Diagnosis and the diagnostic delay and uncertainty experienced by participants; Physical functioning due to the high symptom burden; Psychological and social functioning considering the significant impact on daily life; Treatment and the effect of mogamulizumab; and Support by family, friends and health professionals. Mogamulizumab therapy resulted in a significant decrease of symptoms. The small sample size should also be taken into account although data saturation was reached. This study gives a broad insight into the large impact of E-CTCL and the major consequences on the physical functioning as well as on the emotional\/psychological and social well-being. Mogamulizumab appears to have a positive effect on symptoms.<\/jats:p>","DOI":"10.1002\/ski2.300","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:14:05Z","timestamp":1698322445000},"source":"Crossref","is-referenced-by-count":7,"title":["Unveiling the Hidden Struggles: Exploring the Profound Impact of Advanced Stage Cutaneous T-Cell Lymphoma on Quality of Life"],"prefix":"10.1093","volume":"3","author":[{"given":"Rosanne","family":"Ottevanger","sequence":"first","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith S.","family":"Feenstra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth M.","family":"van Vliet","sequence":"additional","affiliation":[{"name":"Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"van Beugen","sequence":"additional","affiliation":[{"name":"Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea W. M.","family":"Evers","sequence":"additional","affiliation":[{"name":"Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen D.","family":"Quint","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"16","key":"2025010818105509700_ski2300-bib-0001","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2025010818105509700_ski2300-bib-0002","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with Mycosis Fungoides and Sezary Syndrome: a systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"32","key":"2025010818105509700_ski2300-bib-0003","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/jco.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025010818105509700_ski2300-bib-0004","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2025010818105509700_ski2300-bib-0005","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"24","key":"2025010818105509700_ski2300-bib-0006","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1158\/1078-0432.ccr-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sezary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025010818105509700_ski2300-bib-0007","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025010818105509700_ski2300-bib-0008","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010032","article-title":"Quality of life in cutaneous T-cell lymphoma patients receiving mogamulizumab: important factors to consider","volume":"15","author":"Ottevanger","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"2025010818105509700_ski2300-bib-0009","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjd.13732","article-title":"'We had to change to single beds because I itch in the night': a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma","volume":"173","author":"Beynon","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"2025010818105509700_ski2300-bib-0010","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"2","key":"2025010818105509700_ski2300-bib-0011","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"3","key":"2025010818105509700_ski2300-bib-0012","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.141.3.325","article-title":"Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma","volume":"141","author":"Demierre","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"2025010818105509700_ski2300-bib-0013","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.13841","article-title":"Qualitative accounts of living with cutaneous T-cell lymphoma","volume":"173","author":"Barke","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"2025010818105509700_ski2300-bib-0014","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2018.02.011","article-title":"Pruritus in cutaneous T-cell lymphoma and its management","volume":"36","author":"Serrano","year":"2018","journal-title":"Dermatol Clin"},{"key":"2025010818105509700_ski2300-bib-0015","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with Cutaneous T cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int"},{"issue":"9","key":"2025010818105509700_ski2300-bib-0016","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/s1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025010818105509700_ski2300-bib-0017","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/bjd.19298","article-title":"Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma","volume":"184","author":"Bhat","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"2025010818105509700_ski2300-bib-0018","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/jdv.17833","article-title":"Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient-reported outcome measures","volume":"36","author":"Luck-Sikorski","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2025010818105509700_ski2300-bib-0019","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2340\/00015555-2819","article-title":"Patients' illness perception as a tool to improve individual disease management in primary cutaneous lymphomas","volume":"98","author":"Porkert","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"2025010818105509700_ski2300-bib-0020","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2340\/00015555-1673","article-title":"Clinical characteristics associated with illness perception in psoriasis","volume":"94","author":"Wahl","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"16","key":"2025010818105509700_ski2300-bib-0021","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.2217\/fon.14.186","article-title":"Patient-centered care in cancer treatment programs: the future of integrative oncology through psychoeducation","volume":"10","author":"Garchinski","year":"2014","journal-title":"Future Oncol"},{"issue":"6","key":"2025010818105509700_ski2300-bib-0022","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/14737140.2020.1760096","article-title":"Mogamulizumab in the treatment of advanced mycosis fungoides and Sezary syndrome: safety and efficacy","volume":"20","author":"Lewis","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9280","key":"2025010818105509700_ski2300-bib-0023","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/s0140-6736(01)05627-6","article-title":"Qualitative research: standards, challenges, and guidelines","volume":"358","author":"Malterud","year":"2001","journal-title":"Lancet"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/6\/ski2.300\/59727479\/skinhd_3_6_e300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/6\/ski2.300\/59727479\/skinhd_3_6_e300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:11:05Z","timestamp":1736359865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.300\/7755580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.300","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,10,26]]},"article-number":"ski2.300"}}